MedPath

Salbutamol

Generic Name
Salbutamol
Brand Names
Airomir, Airsupra, Combivent, Proair, Proventil, Ventolin
Drug Type
Small Molecule
Chemical Formula
C13H21NO3
CAS Number
18559-94-9
Unique Ingredient Identifier
QF8SVZ843E
Background

Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formulated as a racemic mixture of the R- and S-isomers. The R-isomer has 150 times greater affinity for the beta2-receptor than the S-isomer and the S-isomer has been associated with toxicity. This lead to the development of levalbuterol, the single R-isomer of salbutamol. However, the high cost of levalbuterol compared to salbutamol has deterred wide-spread use of this enantiomerically pure version of the drug. Salbutamol is generally used for acute episodes of bronchospasm caused by bronchial asthma, chronic bronchitis and other chronic bronchopulmonary disorders such as chronic obstructive pulmonary disorder (COPD). It is also used prophylactically for exercise-induced asthma.

Indication

Salbutamol is indicated for (i) the symptomatic relief and prevention of bronchospasm due to bronchial asthma, chronic bronchitis, reversible obstructive airway disease, and other chronic bronchopulmonary disorders in which bronchospasm is a complicating factor, and/or (ii) the acute prophylaxis against exercise-induced bronchospasm and other stimuli known to induce bronchospasm.

Associated Conditions
Asthma, Asthmatic Bronchitis, Bronchial Asthma, Bronchoconstriction, Bronchospasm, Chronic Asthma, Chronic Bronchitis, Cough, Emphysema, Exacerbation of asthma, Exercise-Induced Bronchospasm, Hyperkalemia, Wheezing, Excess mucus or phlegm
Associated Therapies
Airway secretion clearance therapy, Bronchodilation

5 Versus 10 Units of Insulin in Hyperkalemia Management

Phase 4
Recruiting
Conditions
Hyperkalemia
Electrolyte Imbalance
Potassium Imbalance
Electrolyte Disturbance
Interventions
First Posted Date
2023-09-14
Last Posted Date
2023-10-03
Lead Sponsor
Oman Medical Speciality Board
Target Recruit Count
336
Registration Number
NCT06036823
Locations
🇴🇲

Sultan Qaboos University hospital, Seeb, Muscat, Oman

Cardiovascular Consequences of Inhaled Short-acting Beta-agonist Use

Phase 1
Recruiting
Conditions
Healthy
Interventions
Drug: Budesonide/formoterol
Drug: Placebo
First Posted Date
2023-09-07
Last Posted Date
2025-05-07
Lead Sponsor
University of Alberta
Target Recruit Count
90
Registration Number
NCT06027606
Locations
🇨🇦

Clinical Physiology Laboratory, Edmonton, Alberta, Canada

A Clinical Trial of TQC3721 Suspension for Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease.

Phase 2
Completed
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Drug: TQC3721 matching placebo for inhalation
Drug: TQC3721 suspension for inhalation
First Posted Date
2023-08-14
Last Posted Date
2025-04-17
Lead Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Target Recruit Count
75
Registration Number
NCT05987371
Locations
🇨🇳

Suining Central Hospital, Suining, Sichuan, China

🇨🇳

The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China

🇨🇳

The Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, China

and more 8 locations

Reversibility of Methacholine Induced Bronchoconstriction

Phase 4
Active, not recruiting
Conditions
Asthma
Interventions
First Posted Date
2023-08-04
Last Posted Date
2024-12-06
Lead Sponsor
University of Saskatchewan
Target Recruit Count
20
Registration Number
NCT05977699
Locations
🇨🇦

Asthma Research Lab University of Saskatchewan Room 346 Ellis Hall, Saskatoon, Saskatchewan, Canada

Evaluating Bronchodilator Response in Patients With Bronchiectasis

Not Applicable
Recruiting
Conditions
Cystic Fibrosis
Primary Immune Deficiency
Bronchiolitis Obliterans
Bronchiectasis
Primary Ciliary Dyskinesia
Interventions
Diagnostic Test: spirometry
Drug: placebo
First Posted Date
2023-07-06
Last Posted Date
2023-07-06
Lead Sponsor
Rambam Health Care Campus
Target Recruit Count
96
Registration Number
NCT05932316
Locations
🇮🇱

Rambam Health Campus, Haifa, Israel

Effect of Salbutamol on Walking Capacity in Ambulatory ALS Patients

Phase 2
Not yet recruiting
Conditions
Walking Capacity
Amyotrophic Lateral Sclerosis
Interventions
Drug: Placebo
First Posted Date
2023-05-16
Last Posted Date
2024-04-12
Lead Sponsor
Assistance Publique - Hôpitaux de Paris
Target Recruit Count
36
Registration Number
NCT05860244
Locations
🇫🇷

Hôpital Pitié Salpêtrière, Paris, France

Treating Exacerbations of Asthma With Oral Montelukast in Children

Phase 2
Recruiting
Conditions
Status Asthmaticus
Interventions
First Posted Date
2023-04-19
Last Posted Date
2024-05-14
Lead Sponsor
Vanderbilt University Medical Center
Target Recruit Count
90
Registration Number
NCT05819541
Locations
🇺🇸

Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, Tennessee, United States

Green (Sustainable) VENTOLIN - Pharmacokinetics (PK) Study in Healthy Participants

Phase 1
Completed
Conditions
Asthma
Interventions
First Posted Date
2023-03-30
Last Posted Date
2023-11-29
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
28
Registration Number
NCT05791565
Locations
🇳🇱

GSK Investigational Site, Groningen, Netherlands

The Effect of Nebulized Epinephrine in Asthma Exacerbation in Pediatric Age Group With the Standard Treatment Compared to Standard Treatment Using Improvement PRAM Score as a Primary Outcome

Phase 4
Recruiting
Conditions
Asthma in Children
Shortness of Breath
Epinephrine Causing Adverse Effects in Therapeutic Use
Salbutamol Adverse Reaction
Interventions
First Posted Date
2022-12-29
Last Posted Date
2024-04-09
Lead Sponsor
Oman Medical Speciality Board
Target Recruit Count
30
Registration Number
NCT05667727
Locations
🇴🇲

Royal Hospital, Muscat, Oman

INhaled Salbutamol vs Placebo for the Treatment of Acute IgE-mediated Abdominal Pain From Allergic Food REactions

Phase 3
Terminated
Conditions
IgE-mediated Abdominal Pain
Interventions
Drug: Placebo
First Posted Date
2022-12-15
Last Posted Date
2025-05-21
Lead Sponsor
Philippe Bégin
Target Recruit Count
24
Registration Number
NCT05653024
Locations
🇨🇦

CHU Sainte-Justine, Montréal, Quebec, Canada

© Copyright 2025. All Rights Reserved by MedPath